[Alpha Tau in Globe Newswire] Alpha Tau announces FDA Approval of IDE supplement to expand Alpha DaRT® IMPACT trial to patients with pancreatic cancer receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
JERUSALEM, April 23, 2026 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that the FDA has approved an Investigational Device Exemption (IDE) supplement to its U.S. multi-center pancreatic cancer pilot study, known as IMPACT (Intratumoral Pancreatic Alpha Combination Trial), evaluating the safety, feasibility, and efficacy of Alpha DaRT in combination with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma. Read...
Read More